Owen Sansom,2,
Jim Selfridge,1
Isabel M. Caballero,3
Sergey Salozhin,4
Dana Aithozhina,4
Leandro Cerchietti,5
Fan Guo Meng,5
Leonard H. Augenlicht,6
John M. Mariadason,6
Brian Hendrich,3
Ari Melnick,5
Egor Prokhortchouk,4
Alan Clarke,2 and
Adrian Bird1*
Wellcome Trust Centre for Cell Biology, The King's Buildings, Edinburgh University, Edinburgh, United Kingdom,1 Cardiff School of Biosciences, Cardiff University, Cardiff, Wales, United Kingdom,2 Center "Bioengineering," Russian Academy of Sciences, Moscow, Russia,4 Department of Developmental and Molecular Biology and Medical Oncology, Albert Einstein College of Medicine, Bronx, New York 10461,5 Institute for Stem Cell Research, University of Edinburgh, King's Buildings, West Mains Road, Edinburgh EH9 3JQ, United Kingdom,3 Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, New York 104676
Received 27 May 2005/ Returned for modification 9 July 2005/ Accepted 10 October 2005
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Kaiso was first isolated through its ability to interact with the Armadillo-repeat catenin p120 (5). The interaction was surprising as p120-catenin associates with cadherins at the cell membrane, whereas Kaiso behaves as a DNA-binding protein. This raised the possibility that the p120-catenin:Kaiso pair may functionally resemble the ß-catenin:LEF/TCF system by participating in the transmission of extracellular signals from the cell membrane to the nucleus, where Kaiso could act as a regulator of target genes (1). Immunostaining experiments have shown that Kaiso can be either nuclear or cytoplasmic, its intracellular localization and levels of expression being determined by unidentified factors that respond to the cellular microenvironment (44). Support for Kaiso's role in responding to signals from the cell surface has come from studies in Xenopus which showed that the xWnt11 gene, a target of noncanonical Wnt signaling, is regulated by Kaiso (22). Kaiso-mediated repression of xWnt11 and other targets of canonical Wnt signaling are antagonized by p120-catenin (22), which is consistent with the finding that p120-catenin competes with DNA for access to the Kaiso zinc finger domain (6). Repression of the Xenopus genes xWnt11 and Siamois appears to be DNA methylation independent (32), but Kaiso has also been shown to repress transcription of methylated genes (33, 53). In addition, Kaiso has been detected in HeLa cells as part of a multiprotein histone deacetylation complex, where it directly interacts with N-CoR. Likely Kaiso target genes in mammalian cells include S100A4, MTA2, Matrilysin, and the synapse-specific gene Rapsyn (22, 37, 45). Interestingly, Kaiso is reported to be a transcriptional activator at the Rapsyn promoter (37).
Methyl-CpG binding proteins have been implicated in a variety of cellular processes using the technique of gene disruption in mice. For example, Mbd4 deficiency causes an increase in mutation at methyl-CpG sites and reduces the apoptotic response to DNA damage (28, 40, 51), Mbd2 deficiency causes premature activation of the interleukin-4 and gamma interferon genes in T cells (14), and Mbd1 deficiency causes defects in neurogenesis (54). A lethal phenotype is demonstrated by Mecp2-null mice, which acquire neurological defects at 6 weeks of age and show misregulation of several genes in brain tissue (3, 12, 26, 31). Depletion of Kaiso in Xenopus embryos leads to premature gene activation at the blastula stage (38), abnormal gastrulation, and early embryonic lethality. It was therefore proposed that Kaiso is an essential component of a developmental gene regulatory pathway that controls vertebrate morphogenesis (22). Here, we show that deletion of the mouse Kaiso gene does not result in any obvious phenotype. Nor does absence of Kaiso detectably alter expression of the putative target genes Wnt11, S100A4, MTA2, or Rapsyn. Kaiso is therefore dispensable for mouse morphogenesis. Kaiso-deficient mice do, however, show resistance to intestinal tumorigenesis when bred onto an ApcMin/+ genetic background, indicating a role in tumor development. This effect is reminiscent of the tumor resistance seen in Mbd2-deficient mice (39). Consistent with a contribution of Kaiso expression to tumorigenesis, we also observe elevated Kaiso expression in mouse intestinal tumors and expression in a series of human colorectal tumors. Together, our data indicate that Kaiso augments tumorigenesis in the colon.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Chromatin immunoprecipitation. Chromatin was prepared from Kaiso-FLAG animals (livers and lungs) as described by the manufacturer (http://www.upstate.com/misc/protocols.q.prot.e.chips/Chromatin+Immunoprecipitation++ChIPs++ Assay+Kit). Chromatin was immunoprecipitated with 20 µg of anti-Flag antibody (M2; Sigma) overnight at 4°C on a rotating platform. Subsequent steps for recovery of the immunoprecipitated DNA were performed as described in the Upstate protocol cited above. The PCR conditions consisted of 95°C for 5 min, followed by 25 cycles at 95°C for 30 s, 64°C for 30 s, and 72°C for 30 s. The IAP chromatin immunoprecipitation primers were 5'-AGCCGCCCCCACATTCGCCGT and 5'-TCACTCCCTGATTGGCTGCAGC.
Reverse transcriptase PCR. Total RNA was isolated from mouse liver by TRIzol reagent (Invitrogen) according to the manufacturer's protocol. For first-strand synthesis, the RevertAid First-Strand cDNA synthesis kit (Fermentas) was used. Total RNA (1 to 1.5 µg) plus 0.2 µg of random hexamers were incubated for 5 min at 70°C, chilled, and mixed with 4 µl of 5x reaction buffer, 2 µl of 5 mM deoxynucleoside triphosphates, and 200 U of RevertAid M-MuLV reverse transcriptase. The reaction mix was incubated at 25°C for 5 min at 42°C for 60 min and then at 70°C for 10 min. Freshly synthesized cDNA was used as a template for PCR. The PCR conditions consisted of 95°C for 5 min, followed by 25 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 30 s. The primers for IAP Q-PCR were 5'-TGTACCCCGAGCACCAAGAGT and 5'-ATAGGATCCGGGCCATACCAT. The primers for 18S rRNA Q-PCR were 5'-AGACGATCAGATACCGTCGTA and 5'-TGAGGTTTCCCGTGTTGAGTCA. The primers for Wnt11 were 5'-AGCTGGAGGGCCTGGTGTCTGC and 5'-AGGCCCGGGCGATGGTGTG.
Real-time PCR was performed with an ABI Prism 7000 using SYBR Green I. Mean values of CT (cycle threshold) and standard deviations were calculated for duplicate samples. Analysis was performed with independent RNA samples from two mice, with equivalent results. Depicted data represent analysis of one animal.
Clinical samples. Informed consent was obtained from patients to obtain normal and malignant tissue prior to surgical resection of their colon carcinomas in accordance with and under the supervision of the Institutional Review Board of the Montefiore Medical Center.
Kaiso gene disruption. A mouse genomic DNA fragment containing the Kaiso locus was identified through screening of the RPCI-21 genomic PAC library with 32P-labeled Kaiso cDNA. Clone 382-D23 was subcloned to generate the targeting vector. We first cloned two fragments (all coordinates assume the Kaiso translational start ATG codon as 0): a SmaI fragment (2041 to 116) and a SacII fragment (+2391 to + 3673) were subcloned into the pBS/SK plasmid. A neo/tk selectable marker cassette was created by excising the tk gene from plasmid pBT/SPtk(XbaI) using XbaI and cloning it into pBT/MTneo(RI)Version17 at the EcoRV site. An XbaI-HindIII fragment containing the neo and tk genes was then cloned into pBS246 (Invitrogen). A NheI-ScaI fragment from the resulting plasmid was subcloned into pBS246 to generate pBS246-neo/tk, which contained three loxP sites flanking a BamHI site and the neo/tk cassette. A C-terminal Flag tag was added to the Kaiso cDNA (115;+2394) by introducing a synthetic double-stranded Flag oligonucleotide at an artificially introduced EcoRI site at position +2013. The resulting tagged Kaiso cDNA was subcloned into pBS246-neo/tk through BamHI. Finally, Kaiso cDNA and neo/tk were excised by NotI and cloned into the NotI site of plasmid pBS/SK. The vector was linearized prior to transfection.
We carried out gene targeting in the embryonic stem (ES) cell line E14 TG2a from mouse substrain 129/Ola. Cells were grown on gelatinized dishes without feeder cells in the presence of recombinant human LIF (a gift from A. Smith) in standard ES cell conditions. ES cells (10e7cells) were transfected with the linearized targeting vector (250 µg of DNA in 0.8 ml of HEPES buffered saline) by electroporation (800 V, 3 µF; Bio-Rad Gene Pulser) and plated in 10-cm dishes at 5 x 106 cells per dish. Correctly targeted clones were identified by PCR with the following primers: 1, TCAAAGGAAGGCGACCAAGGAGAT; 2, AGCAGTACCATCCTGTTCTG; 3, CTGTCACAGGTTAAAAGC; 4, GTAAGATTCTGGTATTAT; and 5, ATAGTTTAAAGGCATATAGTGGCC. The position of the primers is shown in Fig. 1A. Three primer sets were used for the amplification: 1-5, 1-2, and 3-4. The extension time was calibrated so that only a short (620-bp) DNA fragment was amplified when the 1-5 set was used without amplification of Kaiso coding sequences or the neo/tk cassette. The LoxP flanked allele was identified as an 880-bp band in the 1-2 set, while the intact locus gave rise to a smaller (676-bp) band.
|
Assay for intestinal tumorigenesis. Kaiso-null mice segregating equally for C57BL/6 and Ola129 genomes were mated to ApcMin/+ mice on an inbred C57BL/6J background. Progeny from this cross were then interbred to generate cohorts of ApcMin/+, Kaiso+/y (20 mice plus 23 for the 180-day experiment), and ApcMin/+ Kaiso/y (21 mice plus 18 for the 180-day experiment) mice. These cohorts were therefore segregating for C57BL/6 (75%) and 129/Ola (25%) genomes. All mice were confirmed as congenic for the C57BL/6 Mom-1 allele via PCR analysis. Two experiments were performed: (i) mice were sacrificed when they displayed overt signs of illness and (ii) mice were culled at 180 days. Intestinal tumor burden was determined by removing the entire intestine and mounting en face. Preparations were fixed in methacarn (methanol-chloroform-glacial acetic acid [4:2:1]), and the lesion number and size were scored macroscopically.
Intestines fixed in methacarn were wound into a "gut roll" and paraffin-embedded for histological analysis and immunohistochemistry. To determine crypt size and the levels of apoptosis and mitosis, gut rolls were stained with hematoxylin and eosin, and then the numbers of apoptotic bodies and mitotic figures were determined. Crypt size, apoptotic bodies, and mitotic figures in normal crypts were scored per 25 full crypts. For each adenoma, the number of apoptotic bodies per 500 cells was scored, and for each mouse at least three adenomas were scored, producing an average value per mouse. At least three mice were used for each time point.
Western blots. Frozen aliquots of human colorectal tissue were thawed, and total cellular protein was isolated in immunoprecipitation buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1% IGEPAL, 0.5% sodium deoxycholate, 1 mM EDTA, 5 µg of leupeptin/ml, 1 µg of aprotinin/ml, 1 µM phenylmethylsulfonyl fluoride, and 0.7 µg of pepstatin/ml). Equal protein amounts were then subjected to SDS-polyacrylamide gel electrophoresis and Western blotting with anti-Kaiso monoclonal antibody 6F (Upstate, Lake Placid, NY). Colo 201, Colo 205, Colo 320, DLD-1, HCT15, HCT116, and SW48 cells were grown in Dulbecco modified Eagle medium with 10% fetal bovine serum (Gemini Biosciences). Cells were lysed in 50 mM Tris-HCl (pH 7.4)-NP-40 1%-sodium deoxycholate 0.25%-NaCl 150 mM buffer with protease inhibitors and assayed by Western blotting with the Kaiso 6F monoclonal antibody.
Gel shift analysis of cell line extracts. Kaiso-deficient mouse tail fibroblasts were prepared and immortalized with simian virus 40 virus as described previously (11). The CG11 (nonmethylated) and MeCG11 (methylated) probes were prepared and labeled as described previously (27). The gel shift was performed in agarose gels as described previously (11).
Immunohistochemistry. Colorectal tumors and matched normal mucosa from Muc2/ mice were fixed in 4% neutral buffered formalin, processed, embedded in paraffin wax, sectioned, and stained with hematoxylin and eosin. For Kaiso expression, tissue sections were deparaffinized and rehydrated through a xylene and graded ethanol series. For antigen retrieval, slides were immersed in citrate buffer (pH 6) and brought to boil in a steamer for 20 min. Slides were cooled to room temperature in a running water bath for 15 min and then incubated with 3% hydrogen peroxide in methanol to quench endogenous peroxidase activity for 15 min. After three washes with phosphate-buffered saline (PBS), slides were incubated with permeabilization buffer (0.5% Triton X-100, 20 mM HEPES [pH 7.4], 50 mM NaCl, 3 mM MgCl2, 300 mM sucrose) for 20 min at room temperature. After one wash with PBS, slides were incubated with universal blocking solution (CAS Block; Zymec Laboratories, California) for 10 min at room temperature. The solution was drained, and primary immunoglobulin G1 (IgG1) mouse monoclonal anti-Kaiso antibody (1:200 dilution in PBS; Upstate) or mouse IgG was added as a negative control (1:200 dilution in PBS; Jackson Immunoresearch). Slides were then incubated at 4°C overnight. After three washes with PBS, the slides were incubated for 1 h with biotinylated goat anti-mouse antibody (1:250 dilution in PBS; Zymed Laboratories) at room temperature. Slides were washed three more times with PBS and then incubated for 1 h with preformed avidin-biotinylated peroxidase complex (Vectastain ABC; Vector Laboratories) at room temperature. Color was developed by the addition of diaminobenzoate chromogen peroxidase substrate (Vector Laboratories). Slides were then counterstained with 10% Harris hematoxylin (Lerner Laboratories), dehydrated through a graded ethanol series and xylene, mounted (VectaMount; Vector Laboratories), and visualized by using a light microscope (Zeiss Axioskop).
Neural stem cells assay. Monolayer differentiation to neuroectoderm and isolation of neural stem cell lines was performed as described previously (4, 52). Antibodies against RC2 and Nestin were obtained from the Developmental Studies Hybridoma Bank, the anti-ß-tubulin III was obtained from Covance, and the anti-Gfap antibody was obtained from Sigma.
Confocal immunofluorescence. Kaiso-deficient cells were plated at 103 cells per coverslip and grown for 12 h. A plasmid expressing a green fluorescent protein (GFP)-Kaiso fusion was generated by inserting the human Kaiso coding region in frame with a FLAG coding sequence into pFLAG-CMV2 vector (Sigma) with subsequent cloning of the GFP gene in frame at 3' end of Kaiso to give an N-terminal GFP tag. The cells were transfected with the GFP-Kaiso construct by using Lipofectamine reagent (Invitrogen) according to the manufacturer's instructions. Two days after transfection the cells were fixed in 3% paraformaldehyde for 30 min, followed by two washes with PBS-glycine, permeabilized in 0.2% Triton X-100 for 5 min, and blocked with 3% milk solution. Monoclonal antibody 6H11 against p120-catenin (kindly provided by A. B. Reynolds) was used at 2 µg/ml. Secondary goat anti-mouse IgG labeled with Alexa 594 (Molecular Probes) was diluted 1:600. The slides were mounted with Vectashield reagent (Vector Laboratories) and examined with Leica DM IRE 2 confocal microscope with a x100 oil immersion objective lens.
| RESULTS |
|---|
|
|
|---|
100-kDa Kaiso protein was confirmed in liver nuclear extracts derived from the mutant mice by using antisera raised against amino acids 124 to 492 of Kaiso (Fig. 1D). We further showed that the protein-DNA complex seen in wild-type (wt) mice between Kaiso and the methylated probe MeCG11 (KGB) (33) was absent in extracts from mutant mice (Fig. 1E). An anti-Kaiso antibody supershifted the wt KGB complex but had no effect on complexes formed in mutant extracts (Fig. 1E). Kaiso-null mice showed no overt phenotype and could be maintained as a robust line for >10 generations. The mice were of normal weight and gave birth to litters of normal size. Analysis of Kaiso-null mice at the cellular level. The corepressor N-CoR has been biochemically purified in association with Kaiso and shown to mediate Kaiso repression (53). Since N-CoR has been implicated in development of the central nervous system, erythrocytes, and thymocytes (16), we sought to determine whether Kaiso deficiency affected these tissues. Analysis of blood cells in Kaiso-null mice showed no significant difference from wt mice with respect to the composition of the leukocyte and erythrocyte fractions or erythrocyte morphology (see Fig. S1 in the supplemental material).
We next tested the developmental potential of Kaiso-null stem cells, since N-CoR is implicated in development of the nervous system (16). Also, mice deficient for the methyl-CpG binding protein Mbd1 are viable and fertile but show a defect in adult neurogenesis and hippocampal function, and Mbd1-null neural stem cells show reduced neuronal differentiation compared to wt cells (54). To test for a comparable phenotype in Kaiso-null cells, ES cells in which GFP is expressed from the Sox1 locus (52) were targeted with the floxed Kaiso construct. Properly targeted cells were transfected with a Cre-expression plasmid to induce deletion of the Kaiso gene. The genotype of targeted cells was confirmed by PCR and Southern blotting (as in Fig. 1B), and loss of Kaiso expression was verified by reverse transcription-PCR (RT-PCR) (Fig. 2B). Both Kaiso+/y Sox1GFP and Kaiso/y Sox1GFP ES cell lines were then induced to differentiate into neural ectoderm as described previously (52). Since Sox1 is a specific marker of neural specification, cells that become GFP positive have differentiated into neural precursor cells and can be quantified by fluorescence-activated cell sorting analysis. We found that both Kaiso+/y Sox1GFP and Kaiso/y Sox1GFP ES cells differentiated into Sox1GFP-positive neural precursors at similar frequencies (Fig. 2A). After 12 days, cultures were fixed and stained for markers of postmitotic neurons (ß-tubulin III; Fig. 2C and D) and astrocytes (GFAP; Fig. 2E and F). Both astrocytes and neurons were produced efficiently in Kaiso-null cultures, indicating that Kaiso is not important for cell fate decisions by this assay.
|
We also addressed the effects of Kaiso on localization of p120-catenin in fibroblasts derived from Kaiso-null mice. Transient transfection of a construct expressing a GFP-Kaiso fusion protein had no detectable effect on the cytoplasmic localization of p120-catenin, since transfected and neighboring untransfected cells were indistinguishable in this respect (see Fig. S2 in the supplemental material). Kaiso localization in this assay was predominantly nuclear. Our findings are compatible with a previous report that p120-catenin and Kaiso do not colocalize (44).
Kaiso deficiency does not affect expression of candidate target genes. Kaiso has been implicated in the regulation of several genes using mammalian cultured cell systems. We initially sought to determine whether Kaiso deletion influenced transcription of the putative targets S100A4, Mta2, and Rapsyn (35, 37, 53) in tissues from Kaiso-null mice. Northern blot analysis revealed no change in expression of Mta2 in RNA from brain, liver, or spleen (Fig. 3A). Rapsyn mRNA, which is normally expressed in muscle, was not affected by the absence of Kaiso and S100A4 expression, which is high spleen (9), was also indistinguishable between wt and Kaiso-null animals (Fig. 3A). To look for global effects of Kaiso deficiency, we examined expression of IAP transposable elements, which is normally suppressed by DNA methylation (50). Chromatin immunoprecipitation established that FLAG-tagged Kaiso expressed from the floxed allele was associated with IAP element sequences in chromatin from liver (Fig. 3B). Semiquantitative PCR analysis, however, failed to detect any difference in IAP expression when wt and Kaiso-null liver RNA preparations were compared (Fig. 3B). A particularly well-characterized Kaiso target gene is xWnt11, which binds Kaiso and is upregulated by its absence in Xenopus embryos (22). Moreover, the human Wnt11 gene has been immunoprecipitated from cross-linked HeLa cell chromatin by anti-Kaiso antibodies (22). Examination of Wnt11 expression in Kaiso-null tissues by RT-PCR showed no obvious effect of Kaiso deficiency by either semiquantitative RT-PCR using heart cDNA (Fig. 3C) or quantitative real-time PCR using cDNA from heart, liver, and testis (Fig. 2D). We conclude that in the mouse Kaiso does not play a dominant role in the regulation of these candidate target genes.
|
|
|
| DISCUSSION |
|---|
|
|
|---|
5,000 cell mid-blastula transition in frogs. Thus, the role of Kaiso in ensuring delayed activation of genes in frogs may have no counterpart in mice. Regarding the role of Kaiso in transcriptional repression, we were surprised to find no difference in expression of four genes that were previously identified as Kaiso targets (S100A4, Mta2, Rapsyn, and Wnt11). This suggests either that these genes are not targets of Kaiso-mediated repression in the mouse or that there is a level of redundancy in their control. It is not possible to predict which proteins might substitute for the absence of mouse Kaiso, but the related protein CIBZ/Zenon may be a potential candidate (21, 42). It is clear that deficiency of N-CoR is not equivalent to loss of Kaiso, as Kaiso-null mice show none of the abnormalities observed in N-CoR-null embryos, which die before birth (16). N-CoR is also implicated in the regulation of neurogenesis and in blood differentiation (16), both of which appear normal in Kaiso-null mice.
Our data implicate Kaiso in intestinal tumorigenesis, since its absence inhibits the formation of adenomatous polyps in a mouse model of familial adenomatous polyposis, and both mouse and human colorectal tumors express Kaiso. Given the ability of Kaiso to mediate DNA methylation-dependent transcriptional repression (33, 53) and the known dependence of mouse intestinal tumorigenesis on Dnmt1 (7, 24) and Mbd2 (39), it is tempting to speculate that Kaiso plays a part in the gene silencing that contributes to the cancer phenotype. Studies of repression of the MTA2 gene in HeLa cells are compatible with this view (53). MTA2 is a component of the ubiquitously expressed Mi-2/NuRD complex, and its DNA methylation-dependent repression in HeLa cells is therefore likely to be an abnormal gene silencing event of the kind that is common in permanent cell lines (2) and cancer cells (17). Therefore, Kaiso may mediate abnormal gene silencing that occurs in cancer cells. The finding that Kaiso-null Min tumors exhibit the same mitotic and apoptotic indices as wt Min tumors suggests that Kaiso does not delay tumor growth. It is therefore possible that Kaiso augments the early stages of tumorigenesis. Kaiso has been implicated in Wnt signaling (8, 19, 22, 32, 45), which is important for the normal differentiation program of intestinal epithelium (36). Since polyps in Min mice are invariably Apc null and therefore hyperactive in Wnt signaling (25), the absence of Kaiso may reduce the impact of this defect and therefore constrain tumor development. Future work will seek to identify the range of Kaiso target genes in the intestine that may contribute to such an effect.
The observation that deficiency of Kaiso attenuates tumorigenesis suggests Kaiso as a possible target for anticancer therapy, as has been suggested for both Dnmt1 and Mbd2. Although the delay of tumorigenesis caused by absence of Kaiso is less pronounced than that due to Dnmt1 or Mbd2, Kaiso has the attraction that its absence does not lead to any deleterious phenotype in the mouse. This contrasts with the embryonic lethality caused by absence of Dnmt1 (24) and abnormal gene expression caused by absence of Mbd2 (14) and may reduce the likelihood that Kaiso antagonists will be toxic.
| ACKNOWLEDGMENTS |
|---|
E.P. was supported by an EMBO Fellowship, and subsequently A.P., D.A., S.S., and E.P. were supported by the Wellcome Trust award GR067436MA. This study was also supported by a CRUK program grant (A.C., A.B., and O.S.), by the Wales Gene Park (A.C.), and by grants from the Wellcome Trust (J.S., A.B., B.H., and I.M.C.).
| FOOTNOTES |
|---|
Supplemental material for this article may be found at http://mcb.asm.org/. ![]()
Present address: Center "Bioengineering," Russian Academy of Sciences, Moscow, Russia. ![]()
Present address: CR-UK Beatson Institute for Cancer Research, Glasgow G61 1BD, United Kingdom. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Antequera, F., J. Boyes, and A. Bird. 1990. High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell 62:503-514.[CrossRef][Medline]
3. Chen, W. G., Q. Chang, Y. Lin, A. Meissner, A. E. West, E. C. Griffith, R. Jaenisch, and M. E. Greenberg. 2003. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 302:885-889.
4. Conti, L., S. M. Pollard, T. Gorba, E. Reitano, M. Toselli, G. Biella, Y. Sun, S. Sanzone, Q. L. Ying, E. Cattaneo, and A. Smith. 2005. Niche-independent symmetrical self-renewal of a Mammalian tissue stem cell. PLoS Biol. 3:e283.[CrossRef][Medline]
5. Daniel, J. M., and A. B. Reynolds. 1999. The catenin p120(ctn) interacts with Kaiso, a novel BTB/POZ domain zinc finger transcription factor. Mol. Cell. Biol. 19:3614-3623.
6. Daniel, J. M., C. M. Spring, H. C. Crawford, A. B. Reynolds, and A. Baig. 2002. The p120(ctn)-binding partner Kaiso is a bi-modal DNA-binding protein that recognizes both a sequence-specific consensus and methylated CpG dinucleotides. Nucleic Acids Res. 30:2911-2919.
7. Eads, C. A., A. E. Nickel, and P. W. Laird. 2002. Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min/+) Dnmt1-hypomorphic Mice. Cancer Res. 62:1296-1299.
8. Gregorieff, A., and H. Clevers. 2005. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev. 19:877-890.
9. Grigorian, M., E. Tulchinsky, O. Burrone, S. Tarabykina, G. Georgiev, and E. Lukanidin. 1994. Modulation of mts1 expression in mouse and human normal and tumor cells. Electrophoresis 15:463-468.[CrossRef][Medline]
10. Hendrich, B., and A. Bird. 1998. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol. Cell. Biol. 18:6538-6547.
11. Hendrich, B., J. Guy, B. Ramsahoye, V. A. Wilson, and A. Bird. 2001. Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes Dev. 15:710-723.
12. Horike, S., S. Cai, M. Miyano, J. F. Cheng, and T. Kohwi-Shigematsu. 2005. Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome. Nat. Genet. 37:31-40.[CrossRef][Medline]
13. Hsieh, C. J., B. Klump, K. Holzmann, F. Borchard, M. Gregor, and R. Porschen. 1998. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res. 58:3942-3945.
14. Hutchins, A. S., A. C. Mullen, H. W. Lee, K. J. Sykes, F. A. High, B. D. Hendrich, A. P. Bird, and S. L. Reiner. 2002. Gene silencing quantitatively controls the function of a developmental transactivator. Mol. Cell 10:81-89.[CrossRef][Medline]
15. Issa, J. P., N. Ahuja, M. Toyota, M. P. Bronner, and T. A. Brentnall. 2001. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 61:3573-3577.
16. Jepsen, K., O. Hermanson, T. M. Onami, A. S. Gleiberman, V. Lunyak, R. J. McEvilly, R. Kurokawa, V. Kumar, F. Liu, E. Seto, S. M. Hedrick, G. Mandel, C. K. Glass, D. W. Rose, and M. G. Rosenfeld. 2000. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 102:753-760.[CrossRef][Medline]
17. Jones, P. A., and S. B. Baylin. 2002. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3:415-428.[Medline]
18. Jones, P. L., G. J. Veenstra, P. A. Wade, D. Vermaak, S. U. Kass, N. Landsberger, J. Strouboulis, and A. P. Wolffe. 1998. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 19:187-191.[CrossRef][Medline]
19. Kelly, K. F., A. A. Otchere, M. Graham, and J. M. Daniel. 2004. Nuclear import of the BTB/POZ transcriptional regulator Kaiso. J. Cell Sci. 117:6143-6152.
20. Kelly, K. F., C. M. Spring, A. A. Otchere, and J. M. Daniel. 2004. NLS-dependent nuclear localization of p120ctn is necessary to relieve Kaiso-mediated transcriptional repression. J. Cell Sci. 117:2675-2686.
21. Kiefer, H., F. Chatail-Hermitte, P. Ravassard, E. Bayard, I. Brunet, and J. Mallet. 2005. ZENON, a novel POZ Kruppel-like DNA binding protein associated with differentiation and/or survival of late postmitotic neurons. Mol. Cell. Biol. 25:1713-1729.
22. Kim, S. W., J. I. Park, C. M. Spring, A. K. Sater, H. Ji, A. A. Otchere, J. M. Daniel, and P. D. McCrea. 2004. Non-canonical Wnt signals are modulated by the Kaiso transcriptional repressor and p120-catenin. Nat. Cell Biol. 6:1212-1220.[CrossRef][Medline]
23. Kondo, Y., and J. P. Issa. 2004. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 23:29-39.[CrossRef][Medline]
24. Laird, P. W., L. Jackson-Grusby, A. Fazeli, S. L. Dickinson, W. E. Jung, E. Li, R. A. Weinberg, and R. Jaenisch. 1995. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81:197-205.[CrossRef][Medline]
25. Luongo, C., A. R. Moser, S. Gledhill, and W. F. Dove. 1994. Loss of Apc+ in intestinal adenomas from Min mice. Cancer Res. 54:5947-5952.
26. Martinowich, K., D. Hattori, H. Wu, S. Fouse, F. He, Y. Hu, G. Fan, and Y. E. Sun. 2003. DNA methylation-related chromatin remodeling in activity- dependent BDNF gene regulation. Science 302:890-893.
27. Meehan, R. R., J. D. Lewis, S. McKay, E. L. Kleiner, and A. P. Bird. 1989. Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs. Cell 58:499-507.[CrossRef][Medline]
28. Millar, C. B., J. Guy, O. J. Sansom, J. Selfridge, E. MacDougall, B. Hendrich, P. D. Keightley, S. M. Bishop, A. R. Clarke, and A. Bird. 2002. Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice. Science 297:403-405.
29. Nan, X., H.-H. Ng, C. A. Johnson, C. D. Laherty, B. M. Turner, R. N. Eisenman, and A. Bird. 1998. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393:386-389.[CrossRef][Medline]
30. Ng, H.-H., Y. Zhang, B. Hendrich, C. A. Johnson, B. M. Burner, H. Erdjument-Bromage, P. Tempst, D. Reinberg, and A. Bird. 1999. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat. Genet. 23:58-61.[Medline]
31. Nuber, U. A., S. Kriaucionis, T. C. Roloff, J. Guy, J. Selfridge, C. Steinhoff, R. Schulz, B. Lipkowitz, H. H. Ropers, M. C. Holmes, and A. Bird. 2005. Up-regulation of glucocorticoid-regulated genes in a mouse model of Rett syndrome. Hum. Mol. Genet. 14:2247-2256.
32. Park, J. I., S. W. Kim, J. P. Lyons, H. Ji, T. T. Nguyen, K. Cho, M. C. Barton, T. Deroo, K. Vleminckx, R. T. Moon, and P. D. McCrea. 2005. Kaiso/p120-catenin and TCF/beta-catenin complexes coordinately regulate canonical Wnt gene targets. Dev. Cell 8:843-854.[CrossRef][Medline]
33. Prokhortchouk, A., B. Hendrich, H. Jorgensen, A. Ruzov, M. Wilm, G. Georgiev, A. Bird, and E. Prokhortchouk. 2001. The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressor. Genes Dev. 15:1613-1618.
34. Prokhortchouk, E., and B. Hendrich. 2002. Methyl-CpG binding proteins and cancer: are MeCpGs more important than MBDs? Oncogene 21:5394-5399.[CrossRef][Medline]
35. Prokhortchouk, E. B., A. V. Prokhortchouk, A. S. Rouzov, S. L. Kiselev, E. M. Lukanidin, and G. P. Georgiev. 1998. A minisatellite "core" element constitutes a novel, chromatin-specific activator of mts1 gene transcription. J. Mol. Biol. 280:227-236.[CrossRef][Medline]
36. Riedl, J. A., D. T. Brandt, E. Batlle, L. S. Price, H. Clevers, and J. L. Bos. 2005. Down-regulation of Rap1 activity is involved in ephrinB1-induced cell contraction. Biochem. J. 389:465-469.[CrossRef][Medline]
37. Rodova, M., K. F. Kelly, M. VanSaun, J. M. Daniel, and M. J. Werle. 2004. Regulation of the rapsyn promoter by kaiso and delta-catenin. Mol. Cell. Biol. 24:7188-7196.
38. Ruzov, A., D. S. Dunican, A. Prokhortchouk, S. Pennings, I. Stancheva, E. Prokhortchouk, and R. R. Meehan. 2004. Kaiso is a genome-wide repressor of transcription that is essential for amphibian development. Development 131:6185-6194.
39. Sansom, O. J., J. Berger, S. M. Bishop, B. Hendrich, A. Bird, and A. R. Clarke. 2003. Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nat. Genet. 34:145-147.[CrossRef][Medline]
40. Sansom, O. J., J. Zabkiewicz, S. M. Bishop, J. Guy, A. Bird, and A. R. Clarke. 2003. MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine. Oncogene 22:7130-7136.[CrossRef][Medline]
41. Sarraf, S. A., and I. Stancheva. 2004. Methyl-CpG binding protein MBD1 couples histone H3 methylation at lysine 9 by SETDB1 to DNA replication and chromatin assembly. Mol. Cell 15:595-605.[CrossRef][Medline]
42. Sasai, N., E. Matsuda, E. Sarashina, Y. Ishida, and M. Kawaichi. 2005. Identification of a novel BTB-zinc finger transcriptional repressor, CIBZ, that interacts with CtBP corepressor. Genes Cells 10:871-885.
43. Sato, F., D. Shibata, N. Harpaz, Y. Xu, J. Yin, Y. Mori, S. Wang, A. Olaru, E. Deacu, F. M. Selaru, M. C. Kimos, P. Hytiroglou, J. Young, B. Leggett, A. F. Gazdar, S. Toyooka, J. M. Abraham, and S. J. Meltzer. 2002. Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma. Cancer Res. 62:6820-6822.
44. Soubry, A., J. van Hengel, E. Parthoens, C. Colpaert, E. Van Marck, D. Waltregny, A. B. Reynolds, and F. van Roy. 2005. Expression and nuclear location of the transcriptional repressor Kaiso is regulated by the tumor microenvironment. Cancer Res. 65:2224-2233.
45. Spring, C. M., K. F. Kelly, I. O'Kelly, M. Graham, H. C. Crawford, and J. M. Daniel. 2005. The catenin p120ctn inhibits Kaiso-mediated transcriptional repression of the beta-catenin/TCF target gene matrilysin. Exp. Cell Res. 305:253-265.[CrossRef][Medline]
46. Su, L. K., K. W. Kinzler, B. Vogelstein, A. C. Preisinger, A. R. Moser, C. Luongo, K. A. Gould, and W. F. Dove. 1992. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256:668-670.
47. Thoreson, M. A., and A. B. Reynolds. 2002. Altered expression of the catenin p120 in human cancer: implications for tumor progression. Differentiation 70:583-589.[CrossRef][Medline]
48. Velcich, A., W. Yang, J. Heyer, A. Fragale, C. Nicholas, S. Viani, R. Kucherlapati, M. Lipkin, K. Yang, and L. Augenlicht. 2002. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 295:1726-1729.
49. Wade, P. A., A. Gegonne, P. L. Jones, E. Ballestar, F. Aubry, and A. P. Wolffe. 1999. Mi-2 complex couples DNA methylation to chromatin remodeling and histone deacetylation. Nat. Genet. 23:62-66.[Medline]
50. Walsh, C. P., J. R. Chaillet, and T. H. Bestor. 1998. Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. Nat. Genet. 20:116-117.[CrossRef][Medline]
51. Wong, E., K. Yang, M. Kuraguchi, U. Werling, E. Avdievich, K. Fan, M. Fazzari, B. Jin, A. M. Brown, M. Lipkin, and W. Edelmann. 2002. Mbd4 inactivation increases C
T transition mutations and promotes gastrointestinal tumor formation. Proc. Natl. Acad. Sci. USA 99:14937-14942.
52. Ying, Q. L., M. Stavridis, D. Griffiths, M. Li, and A. Smith. 2003. Conversion of embryonic stem cells into neuroectodermal precursors in adherent monoculture. Nat. Biotechnol. 21:183-186.[CrossRef][Medline]
53. Yoon, H. G., D. W. Chan, A. B. Reynolds, J. Qin, and J. Wong. 2003. N-CoR mediates DNA methylation-dependent repression through a methyl CpG binding protein Kaiso. Mol. Cell 12:723-734.[CrossRef][Medline]
54. Zhao, X., T. Ueba, B. R. Christie, B. Barkho, M. J. McConnell, K. Nakashima, E. S. Lein, B. D. Eadie, A. R. Willhoite, A. R. Muotri, R. G. Summers, J. Chun, K. F. Lee, and F. H. Gage. 2003. Mice lacking methyl-CpG binding protein 1 have deficits in adult neurogenesis and hippocampal function. Proc. Natl. Acad. Sci. USA 100:6777-6782.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|